Genoptix Reports Strong Financial Results for the Second Quarter and Raises Guidance for Full-Year 2008

Friday, August 1, 2008 General News
Email Print This Page Comment bookmark
Font : A-A+

CARLSBAD, Calif., July 31 Genoptix, Inc.(Nasdaq: GXDX), a specialized laboratory services provider, today reportedrevenues of $27.8 million for the second quarter of 2008 and $50.1 million forthe first half of 2008, as compared to revenues of $13.9 million and$24.6 million for the respective periods in 2007. Stated revenue for thefirst half of 2008 included a $1.3 million benefit from changes in accountingestimates relating to prior periods.

"Our strong performance in the first half of the year resulted in growthin all segments, as revenues increased by 99% over the second quarter of 2007and 104% over the first half of last year," said Tina Nova Bennett, Ph.D.,President and CEO of Genoptix. "Expanding our sales efforts and improving ourability to provide high quality diagnostic services to a wider audiencecontinues to drive customer growth nationwide. Higher case volumes reflectthe success of these initiatives, increasing 77% year-over-year to more than9,300 cases since the beginning of April, our sixteenth consecutive quarter ofsolid growth in volumes and in revenues."

The Company also reported GAAP net income of $5.6 million for the secondquarter ended June 30, 2008 and $10.6 million for the first half of 2008compared to GAAP net income of $3.8 million for the second quarter ended June30, 2007 and $5.1 million for the first half of 2007. Diluted earnings pershare, or EPS, for the second quarter of 2008 was $0.32 based on 17.5 millionweighted average common shares outstanding, including the $0.14 impact fromincreased costs associated with non-cash stock-based compensation expense,resulting from the launch of our employee stock purchase program following ourinitial public offering, or IPO. Diluted EPS was $0.60 for the first half ofthe year, including $0.19 of non-cash stock-based compensation expense.

The Company completed its IPO on November 2, 2007. On a pro forma basis,assuming conversion of all outstanding preferred stock, diluted EPS for thethree and six months ended June 30, 2007 would have been $0.30 and $0.40,respectively (see "Pro Forma Net Income Per Share" table below).

Gross profit for the second quarter of 2008 improved 94% to $16.6 millionfrom $8.6 million for the second quarter of 2007, or 59.7% of revenues ascompared to 61.3% of revenues, respectively. Gross margins reflect the impactof additional costs associated with stock-based compensation and theinvestment in additional personnel to support our growing operations. For thefirst half of 2008, gross profits totaled $29.7 million, improving 104% ascompared to $14.6 million for the same period in 2007, with gross profit atapproximately 59.3% of revenues for the first half of 2008 being effectivelyflat year-over-year.

Operating expenses for the second quarter of 2008 increased to$11.4 million from $4.7 million in the second quarter of 2007 and to$20.4 million in the first half of 2008 from $9.3 million during the sameperiod in 2007. These expenses were higher primarily due to investment inadditional personnel to support organizational growth efforts, stock-basedcompensation expense and the increased costs associated with operating as apublic company. Operating income for the second quarter of 2008 was$5.2 million, or 18.6% of revenues, as compared to $3.9 million, or 27.7% ofrevenues, during the same period in 2007. Operating income was $9.3 million,or 18.6% of revenues for the first half of 2008, up from $5.2 million, or21.3% of revenues, for the first half of 2007.

As of June 30, 2008, the Company's cash and cash equivalents andinvestment securities available-for-sale totaled $96.1 million. For the sixmonths ended June 30, 2008, cash generated from operations was $12.9 million,while purchases of capital equipment for the same period totaled $2.6 million.The quarter closed with bad debt expense of 3.0% of total revenues and dayssales outstandin

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store